News

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CVS heads into Q2 earnings with estimates pointing to revenue and EPS growth as Aetna initiatives and key business segments support results.

Recent earnings expectations and fresh store openings have put CVS Health (CVS) in focus for investors. The stock now sits near US$105 after a strong past year, raising questions about what is already reflected in the price. See our latest analysis for CVS Health. Over the past year, CVS Health has seen its share price move sharply higher, supported by a 90 day share price return of 28.18% and a 1 year total shareholder return of 74.81%. Recent store openings, product launches and...

Globus Medical will report Q2 results on Aug. 6. Investors will be keen to know whether Enabling Technologies and Spine strength aid revenue & earnings growth.

Beyond analysts' top-and-bottom-line estimates for CVS Health (CVS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

CRL is set to report Q2 results on Aug. 5 as investors watch segment demand, divestitures, and whether the company can extend its earnings beat streak.

Knorr-Bremse AG (KNRRY) achieves highest quarterly operating EBIT margin in five and a half years, while launching a 'Growth Beyond' strategy targeting EUR10 billion in revenue by 2030.

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZBH heads into Q2 earnings with expectations of modest revenue growth as investors watch demand trends across knees, hips and robotics.

Humana reports earnings Wednesday after its stock surged this year on improving confidence in Medicare Advantage insurers. Investors will be watching medical costs and the company’s outlook.

HSIC heads into Q2 earnings with expectations for revenue and EPS growth as dental, specialty products and AI-enabled technology remain in focus.

CVS, CAH, HUM and ACAD look ready for Q2 2026 earnings beats as growing demand for medical products and services continues to support performance.

HCA tops Q2 EPS estimates on higher admissions and revenue per admission but trims parts of its 2026 guidance as higher expenses and weaker surgical volumes weigh on results.

Molina beats Q2 earnings estimates as lower operating expenses offset weaker premium revenues, declining membership and softer investment income, while the company raises its 2026 earnings guidance.

CVS Group (LON:CVSG) said revenue for the financial year ended June 30 exceeded GBP 710 million, up 5.9% from the prior year, as the veterinary services provider used an investor presentation to reiterate its capital allocation policy and outline expected returns from acquisitions and capital invest

LH heads into Q2 earnings results with expectations for higher revenues and EPS, as diagnostics, specialty testing and new collaborations drive momentum.

DHR beats Q2 estimates as Life Sciences posts its strongest quarter in years, prompting the company to raise its 2026 adjusted EPS outlook.

Community Health heads into Q2 earnings with mixed operating trends as stronger occupancy meets lower admissions and a smaller hospital portfolio.

ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.

DHR heads into Q2 earnings with bioprocessing and diagnostics strength, but rising costs and debt could pressure profitability.

Insurance giant UnitedHealth Group (UNH) is out with its second quarter earnings on Thursday, raising its full-year outlook alongside its reported $112 billion in quarterly revenue. The stock has jumped in Thursday trading. Mizuho Americas healthcare equity strategist Jared Holz takes a closer look at the insurer's stock performance and the role Medicare Advantage had in its figures.

Elevance Health raised its profit forecast and the stock promptly fell. Here’s the one number that explains why investors headed for the exits.

UnitedHealth Group crushed Q2 earnings forecasts amid lower-than-expected benefit costs and gave a big boost to its full-year outlook. Humana, Centene and CVS Health all got a sizable lift from the warm reception for UnitedHealth's earnings report.

Elevance Health beats Q2 EPS and revenue estimates, raises 2026 adjusted EPS outlook despite lower earnings, softer membership and higher expenses.

After a rocky start to the year, health insurer stocks have roared back. The insurers are trying to end a difficult cycle that began about three years ago, when healthcare use, and the costs to cover it, accelerated postpandemic. The fund’s top 10 holdings encompass six health insurers, three of which— UnitedHealth Group Aetna parent CVS Health and Elevance Health —comprise more than 40% of the fund.

CVS Health is scheduled to post its second-quarter results in August, and analysts project a single-digit earnings rise.

David Joyner’s assurances, which come about a month before CVS is scheduled to report its second quarter results, will likely be welcomed by investors wary after a difficult few years for insurers.

Before the stock surged, management laid out a turnaround plan for its Aetna unit that was so explicit, they practically put a price tag on it.